Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

  title={Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.},
  author={Milton Packer and Stefan D. Anker and Javed Butler and Gerasimos Filippatos and Stuart J. Pocock and Peter E. Carson and James L. Januzzi and Subodh Verma and Hiroyuki Tsutsui and Martina Brueckmann and Waheed Jamal and Karen Kimura and Janet Schnee and Cordula Zeller and Daniel Cotton and Edimar Alcides Bocchi and Michael B{\"o}hm and Dong Ju Choi and Vijay K. Chopra and Eduardo Chuquiure and Nadia Giannetti and Stefan Janssens and Jian Zhang and Jos{\'e} Ram{\'o}n Gonz{\'a}lez Juanatey and Sanjay Kaul and Hans-Peter Brunner-La Rocca and B{\'e}la Merkely and Stephen J. Nicholls and Sergio V. Perrone and Ileana L. Pi{\~n}a and Piotr Ponikowski and Naveed Sattar and Michele Senni and Marie France S{\'e}ronde and Jindřich {\vS}pinar and Iain B. Squire and Stefano Taddei and Christoph Wanner and Faiez Zannad},
  journal={The New England journal of medicine},
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40… 

Figures and Tables from this paper

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empaglif Lozin significantly improved cardiovascular and renal outcomes in patients with heart failure and a reduced ejection fraction, independent of baseline diabetes status and across the continuum of HbA1c.

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

In patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy.

EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction.

In this phase III, placebo-controlled trial, 3730 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less were randomly assigned to receive either empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy.

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patientsWith an ejection fraction ≥65%.

Empagliflozin: A Review in Symptomatic Chronic Heart Failure

The addition of oral empagliflozin 10 mg/day to standard of care significantly reduced the risk of cardiovascular death or hospitalization for HF (HHF) or cardiovascular death in nonhospitalized patients with HFpEF, HFmrEF or HFrEF, regardless of diabetes status and the standard HF therapies they were already taking.

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

In EMPEROR-Reduced, empagliflozin had a beneficial effect on the key efficacy outcomes and slowed the rate of kidney function decline in patients with and without CKD, and regardless of the severity of kidney impairment at baseline.

Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?

An up-to-date summary of the totality of evidence supporting the use of SGLT2 inhibitors in patients with heart failure is provided.

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.




Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

Patients in EMPA-REG OUTCOME demonstrated a broad risk spectrum for cardiovascular events, and reductions in key cardiovascular outcomes and mortality with empagliflozin versus placebo were consistent across the range of cardiovascular risk.

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

The EMPEROR‐Reduced trial is well‐positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction.

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

The “thrifty fuel hypothesis”, which proposes that enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress, is proposed to explain the cardiorenal benefits of SGLT2 inhibitors.

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

Current evidence from RCTs does not suggest an increased risk of harm with SGLT2 inhibitors as a class over placebo or active comparators with respect to AKI, DKA, UTI or fracture, however, wide CIs for many comparisons suggest limited precision, and therefore clinically important adverse events cannot be ruled out.

Canaglif lozin and cardiovascular and renal events in type 2 diabetes

  • N Engl J Med
  • 2017

Dapaglif lozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction

  • Circulation
  • 2019

Dapaglif lozin in patients with heart failure and reduced ejection fraction

  • N Engl J Med
  • 2019

Effect of dapaglif lozin on heart failure and mortality in type 2 diabetes mellitus

  • Circulation
  • 2019